Analysts at Canaccord downgraded Teva Pharmaceutical Industries (NYSE: TEVA ) from “buy” to “hold.” The target price for Teva has been raised from $50 to $45. Teva's shares closed at $37.96 yesterday. Analysts at FBR Capital downgraded Riverbed Technology (NASDAQ: RVBD ) from “outperform” to “market perform.” The